secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001140361-24-025064
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys Q1 net loss widens to $3.6M; sales down 8%; cash runway into H2 2025
----------------------------------------------------------------------------

- Net loss of $3.6M ($0.17 EPS) vs $2.9M ($0.25 EPS) in Q1 2023; sales $271K vs $294K.
- R&D expenses rose 15% to $1.77M; G&A $1.50M; operating loss $3.46M.
- Cash $17.8M; expects funding operations into second half 2025.
- Positive topline data from FemaSeed pivotal trial; first commercial procedure completed.
- Appointed Richard Spector as CCO; FemBloc pivotal trial enrollment initiated at six sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/0001140361-24-025064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036124025064/ef20028745_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-025064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer